MED-EL
An Austrian medical-technology company specializing in cochlear, middle-ear, bone-conduction and auditory-brainstem implants.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
MED-EL is an Austrian medical-technology company headquartered in Innsbruck and focused on implantable and wearable technologies for people with hearing loss. Its principal activities include the development, manufacture and support of cochlear implants, active middle-ear implants, bone-conduction systems, auditory brainstem implants and related sound processors and accessories. The company serves clinical and consumer markets through a global distribution and support network spanning Europe, the Americas, the Middle East, Asia, Australia and Africa. The company grew out of the cochlear-implant research of Austrian scientists Ingeborg and Erwin Hochmair. During the 1970s, the couple worked at the Technical University of Vienna on microelectronic implants and sound-processing strategies. Their research contributed to the implantation of an early multichannel cochlear implant in Vienna in 1977. Subsequent experiments showed that the relationship between electrode stimulation, sound coding and speech comprehension was more complicated than the researchers had initially expected. The Hochmairs therefore explored simpler implant architectures and alternative stimulation strategies while continuing to pursue practical hearing restoration. A passive transcutaneous four-channel implant developed in 1979 enabled a patient to understand some spoken language without relying on lip-reading in a quiet setting. In 1981, the Vienna research group entered into a licensing and support arrangement with 3M, leading to commercial work around the 3M/Vienna cochlear implant. Although the system provided meaningful benefit to some recipients, 3M ultimately ended its commercial involvement, and competing multichannel systems generally demonstrated stronger performance in complex listening environments. The experience encouraged the Hochmairs to establish an independent company capable of pursuing their own multichannel design and commercialization strategy. MED-EL GmbH was founded in 1989. After Erwin Hochmair became a professor at the University of Innsbruck, the company established its base in Innsbruck and hired its first employees in 1990. A major early milestone came in 1991 with the development of a behind-the-ear audio processor, which moved the external processing unit from a body-worn configuration to a form factor resembling a conventional hearing aid. This helped make cochlear-implant technology more practical and socially familiar for users. The company subsequently expanded beyond conventional cochlear implants. In 1995, it introduced the CIS LINK processor, allowing users of the Ineraid implant to benefit from a newer continuous-interleaved-sampling sound-coding approach. In 1997, MED-EL began producing auditory brainstem implants for people whose auditory nerves or cochleae could not be effectively treated with a conventional cochlear implant. In 2003, it acquired the Vibrant Soundbridge active middle-ear implant, marking its first major non-cochlear implant product. It later added electric-acoustic stimulation, the Bonebridge active bone-conduction implant and the Adhear non-surgical bone-conduction system. MED-EL's current portfolio combines implant hardware, external audio processors, fitting software and clinical support. Its cochlear-implant systems use an implanted electrode array to electrically stimulate the auditory nerve through the cochlea. Electric-acoustic stimulation combines electrical treatment for higher frequencies with acoustic amplification for residual low-frequency hearing. The Vibrant Soundbridge uses a middle-ear actuator to vibrate structures in the middle ear, while Bonebridge directly stimulates bone through a transcutaneous implant. The company also develops systems for auditory-brainstem stimulation and invests in surgical navigation, vestibular prostheses, drug-delivery electrodes, tissue-healing research and totally implantable cochlear implants. MED-EL remains privately held and is led by co-founder Ingeborg Hochmair. The company reports an international user base numbering approximately 200,000 people. In addition to its medical-device operations, it established the Audioversum Science Center in Innsbruck in 2013, an educational and public-facing facility focused on hearing, communication and the science of sound.
History
MED-EL's history is rooted in the Austrian cochlear-implant research of Ingeborg and Erwin Hochmair. In the mid-1970s, the two scientists worked at the Technical University of Vienna on microelectronic systems intended to restore hearing by electrically stimulating the auditory pathway. Their work was associated with the implantation of an early microelectronic multichannel cochlear implant in Vienna in 1977. Initial testing of different coding strategies did not produce reliable open-set speech understanding, prompting a reassessment of the complexity and practicality of the original design. The researchers then examined simpler implant configurations and passive systems that could be more readily constructed and modified. A passive transcutaneous four-channel implant developed in 1979 enabled a recipient to understand some speech without visual assistance in a quiet environment. The result was important but also revealed the limitations of the coding strategy, which effectively emphasized the strongest-performing electrode rather than delivering fully simultaneous multichannel stimulation. In 1981, 3M entered a licensing and support arrangement with the Vienna group. The resulting 3M/Vienna cochlear implant showed that some recipients could achieve useful speech recognition without lip-reading. However, later design changes and comparisons with competing multichannel implants exposed performance limitations, and 3M eventually withdrew from commercial involvement. The Vienna group subsequently pursued a new multichannel approach incorporating continuous-interleaved-sampling principles associated with researcher Blake Wilson. The Hochmairs founded MED-EL GmbH in 1989. The company's Innsbruck base reflected Erwin Hochmair's appointment as a professor at the University of Innsbruck. MED-EL hired its first three employees in 1990 and developed a behind-the-ear audio processor in 1991. This was a significant practical development because it replaced a body-worn external processor with a device positioned behind the ear, closer to the form factor of a conventional hearing aid. MED-EL continued to develop processors and sound-coding technologies. In 1995, its CIS LINK system enabled Ineraid implant users to use continuous-interleaved-sampling processing even though Ineraid had stopped further implant development. The company also entered the auditory-brainstem-implant field in 1997, adapting its implant expertise for patients who could not receive conventional cochlear implants. A major diversification occurred in 2003, when MED-EL acquired the Vibrant Soundbridge active middle-ear implant. The acquisition broadened the company from cochlear implants into other forms of implantable hearing treatment. In 2005, MED-EL introduced an electric-acoustic stimulation system that combined cochlear electrical stimulation for higher frequencies with conventional acoustic amplification for lower frequencies. Bonebridge, an active bone-conduction implant, followed in 2012, and Adhear, a non-surgical bone-conduction system using an adhesive adapter, was introduced in 2017. The company also expanded its public and research activities. Audioversum Science Center opened in Innsbruck in 2013 as a hearing-focused educational center. MED-EL worked with CAScination on Hearo, an image-guided surgical robot for cochlear implantation; the system received a CE mark in 2020. Other research programs described in the company's reference material include vestibular prostheses, the Dexel drug-delivery electrode, regenerative-healing approaches using extracellular vesicles and a totally implantable cochlear implant known as TICI. These projects illustrate MED-EL's effort to extend hearing technology toward less invasive surgery, improved healing, balance restoration and reduced reliance on external hardware.
- 2020
Hearo receives CE mark
[1]The Hearo image-guided surgical robot, developed with CAScination, received the CE mark.
- 2017
Adhear introduced
[1]MED-EL expanded its bone-conduction portfolio with Adhear, a non-surgical device attached behind the ear through an adhesive adapter.
- 2013
Audioversum Science Center opens
[1]MED-EL opened a public science center in central Innsbruck focused on hearing and sound.
- 2012
Bonebridge receives European approval
[1]The Bonebridge active bone-conduction implant became the first implant of its type to offer direct bone stimulation through a transcutaneous system and was approved in Europe.
- 2005
Electric-acoustic stimulation system introduced
[1]MED-EL launched a system combining electrical cochlear stimulation with acoustic amplification.
- 2003
Vibrant Soundbridge acquired
[1]The acquisition added an active middle-ear implant to MED-EL's portfolio.
- 1997
Auditory brainstem implant production begins
[1]MED-EL began producing auditory brainstem implants for users who could not benefit from conventional cochlear implantation.
- 1995
CIS LINK introduced
[1]The CIS LINK processor brought newer continuous-interleaved-sampling processing to users of the Ineraid implant.
- 1991
Behind-the-ear audio processor developed
[1]MED-EL developed an external processor worn behind the ear rather than on the body.
- 1989
MED-EL founded
[1]Ingeborg and Erwin Hochmair established MED-EL GmbH in Innsbruck.
Products and positioning
A privately owned, research-led hearing-implant specialist competing through a broad implant portfolio, long-term clinical support, surgical compatibility and investment in hearing-restoration technologies beyond conventional cochlear implants.
Cochlear implants
Cochlear implant systems
MED-EL's core product category uses an implanted electrode array to convert processed sound into electrical stimulation delivered to the cochlea and auditory nerve. The referenced current platform includes the SYNCHRONY 2 implant, used with external processors such as SONNET 3 and RONDO 3. The SYNCHRONY 2 is described as compatible with MRI scanning at up to 3.0 Tesla under applicable conditions.
Hybrid hearing implants · 2005
Electric-acoustic stimulation systems
Electric-acoustic stimulation combines two forms of treatment in one system. Electrical stimulation addresses higher-frequency hearing through the cochlear implant, while acoustic amplification supports residual low-frequency hearing. The referenced current configuration pairs a SYNCHRONY 2 EAS implant with a SONNET 3 EAS audio processor.
Active middle-ear implant · 2003
Vibrant Soundbridge
Vibrant Soundbridge is an active middle-ear implant acquired by MED-EL in 2003. Its actuator vibrates structures of the middle ear so that mechanical sound energy can reach the cochlea. The referenced current components include the VORP 503 implant and SAMBA 2 audio processor. MED-EL also offers passive middle-ear prostheses that replace some or all ossicles.
Active bone-conduction implant · 2012
Bonebridge
Bonebridge is an implantable bone-conduction system designed to stimulate the skull through a transcutaneous connection. It was introduced as an active direct-drive bone-conduction implant and received European approval in 2012. The referenced current configuration includes the BCI 602 implant and SAMBA 2 audio processor.
Non-surgical bone-conduction device · 2017
Adhear
Adhear is MED-EL's non-surgical bone-conduction hearing system. An adhesive adapter is placed on the skin behind the ear, and the external hearing device attaches to that adapter to transmit vibrations through the skull. Unlike Bonebridge, it does not require an implanted component.
Auditory brainstem implant · 1997
Auditory brainstem implant
MED-EL's auditory brainstem implant is intended for patients who cannot receive effective stimulation through a conventional cochlear implant. Its electrode array is positioned near the cochlear nucleus of the brainstem rather than inserted into the cochlea.
Surgical technology
Hearo
Hearo is an image-guided surgical robot developed through collaboration between MED-EL and Swiss company CAScination. It supports planning and execution of a trajectory for cochlear implantation and is designed to assist surgeons with image-based procedure planning.
Brand decisions
2020
Advance totally implantable cochlear-implant researchOtherBackground
A totally implantable cochlear implant would seek to place audio-processing components inside the body, reducing reliance on an external processor.
Action taken
MED-EL conducted a clinical trial of its TICI concept, with the first European patient implanted in September 2020.
Aftermath
The work remained investigational in the cited material and represented a research direction rather than a confirmed mass-market product launch.
2017
Introduce the Adhear non-surgical bone-conduction systemProduct launchBackground
Some users require bone-conduction support but may not be candidates for, or may not want, an implanted system.
Action taken
MED-EL launched Adhear, using an adhesive behind-the-ear adapter instead of an implanted component.
Aftermath
The product gave MED-EL a non-surgical option within its bone-conduction portfolio.
2012
Commercialize the Bonebridge active bone-conduction implantProduct launchBackground
Bone-conduction treatment provided a way to address selected hearing-loss conditions through direct stimulation of bone rather than conventional acoustic transmission through the outer and middle ear.
Action taken
MED-EL introduced Bonebridge and obtained European approval for the system.
Aftermath
Bonebridge became a major non-cochlear implant line and expanded MED-EL's position in implantable bone-conduction hearing.
2003
Acquire the Vibrant Soundbridge businessM&ABackground
MED-EL's historical portfolio was centered on cochlear implants, while Vibrant Soundbridge offered an active middle-ear implant and a route into non-cochlear implantable hearing treatment.
Action taken
MED-EL acquired Vibrant Soundbridge and incorporated the active middle-ear implant into its product portfolio.
Aftermath
The transaction broadened MED-EL's business into active middle-ear implants and was followed by further expansion into electric-acoustic and bone-conduction systems.
Recent events
Tencent Ethereal Audio Lab and MED-EL unveil hearing aid app[3]
Reported:
Tencent Ethereal Audio Lab and MED-EL unveiled a hearing aid app combining hearing tests, AI-assisted hearing enhancement and remote rehabilitation services. The app was co-developed by the two organizations.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/med-el · Editorial policy · How profiles are compiled